Skip to content
Review Open access

Chronic Paraquat Neurotoxicity and Dopaminergic Degeneration: A Mechanistic Review

Sep 2026 · Chemistry and Biodiversity · Vol 23 · 0 citations · 189 references
Medicine

TL;DR

The current review will summarize the available scientific evidence concerning the use and impacts of chronic exposure to PQ in the light of PD.

Abstract

Parkinson's disease (PD) is a significant neurodegenerative disorder that affects 1%–2% of the entire global population. Despite its higher prevalence, an effective treatment that prevents or reverses neuronal damage is still not available. Clinical characteristics of PD include bradykinesia, postural instability, tremor, and rigidity. This disease is pathologically defined by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and by Lewy pathology with aggregated α‐synuclein (oligomers), although the exact role of Lewy bodies (LB) in cell death is controversial. Like other neurodegenerative disorders, the etiology of PD is associated with genetic, environmental, and other unknown factors. Certain neurotoxins such as rotenone, maneb, 6‐OHDA, MPTP and paraquat are main factors in the causation of PD. Among them, paraquat (PQ) is strongly linked with PD because of its common use in developing countries. Many in vitro and in vivo studies have reported the occurrence of PD due to exposure to PQ. The apoptotic cell death caused by PQ is associated with oxidative stress, ER stress, catabolic changes in dopamine, mitochondrial dysfunction, and so forth. The current review will summarize the available scientific evidence concerning the use and impacts of chronic exposure to PQ in the light of PD.

Read PDF

Similar papers

Open access Sep 2026

The 6-OHDA Model of Parkinson’s Disease: Mechanisms, Applications, and Limitations

Parkinson's disease (PD) is the second most prevalent progressive neurodegenerative disorder, in which the dopaminergic neurons are lost. Genetic and environmental factors are involved in the onset of PD. Symptoms such as tremor, balance problems, nerve pain, muscle stiffness, and mental issues are the most common. Des...

Yi-Yi Ma · 0 citations
Review Open access Oct 2026

Targeting the Gut to Modify Parkinson's Disease: From Mechanisms to Potential Therapeutics.

Parkinson's disease (PD) is the second most common neurodegenerative disorder and its prevalence continues to rise with population aging. Its cardinal motor features arise from the loss of dopaminergic neurons in the substantia nigra, accompanied by intraneuronal α-synuclein aggregates known as Lewy bodies. Neuropathol...

Yi-Cheng Tai, Chin-Hsien Lin · 0 citations
Review Open access Aug 2026

Role of STX1A in Parkinson’s disease: evidence, mechanistic hypotheses, and translational perspectives

The biomarker and therapeutic potential of STX1A remains preliminary because diagnostic performance, disease specificity, longitudinal stability, and causal relevance have not been adequately validated and future studies using cell-type-specific STX1A manipulation, rescue experiments, electrophysiology, and multicenter...

Rui Xu, Rui Li, Hong-Mei Li et al. · 0 citations
Review Open access Sep 2026

Neuroinflammation and metabolic reprogramming in Parkinson’s disease

An integrative model in which neuroinflammation and metabolic dysfunction function not merely in parallel, but as mutually reinforcing components of a self-amplifying pathological circuit is proposed, while acknowledging that this model remains to be fully validated and that alternative causal architectures are possibl...

Yi-Xin Fu, Jiang-Hao Yu, Lu Xu et al. · 0 citations
Review Oct 2026

Dual targeting of melatonergic and serotonergic neurotransmissions in Parkinson's disease: role of agomelatine.

Parkinson's disease (PD) is a progressive neurodegenerative disorder of the central nervous system (CNS), driven by the pathological aggregation and accumulation of α-synuclein (α-Syn) within dopaminergic neurons of the substantia nigra pars compacta (SNpc). Despite extensive research, the pathogenesis of PD remains in...

Hayder M. Al-kuraishy, M. Naji, R. R. Abd Hasan et al. · 0 citations
Review 2026

Peripheral manifestations of nigrostriatal neurodegeneration in Parkinson's disease.

Various categories of biomarkers, including protein aggregates, inflammation-related factors, oxidative stress markers, metabolomic and lipidomic signatures, genetic and epigenetic status, and PD-related exosomes are discussed, could serve as a diagnostic tool for PD and may provide predictive measures of disease outco...

Jerly Helan Mary Joseph, Mahesh Kandasamy · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.